Literature DB >> 31085563

Melanoma.

Robert Micieli1, Kucy Pon2.   

Abstract

Entities:  

Year:  2019        PMID: 31085563      PMCID: PMC6520069          DOI: 10.1503/cmaj.181500

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.

Authors:  Daniela Massi; Lisa Simi; Elisa Sensi; Gianna Baroni; Gongda Xue; Cristian Scatena; Adele Caldarella; Pamela Pinzani; Gabriella Fontanini; Alessandra Carobbio; Carmelo Urso; Mario Mandalà
Journal:  Mod Pathol       Date:  2014-10-24       Impact factor: 7.842

2.  Whole-genome landscapes of major melanoma subtypes.

Authors:  Nicholas K Hayward; James S Wilmott; Nicola Waddell; Peter A Johansson; Matthew A Field; Katia Nones; Ann-Marie Patch; Hojabr Kakavand; Ludmil B Alexandrov; Hazel Burke; Valerie Jakrot; Stephen Kazakoff; Oliver Holmes; Conrad Leonard; Radhakrishnan Sabarinathan; Loris Mularoni; Scott Wood; Qinying Xu; Nick Waddell; Varsha Tembe; Gulietta M Pupo; Ricardo De Paoli-Iseppi; Ricardo E Vilain; Ping Shang; Loretta M S Lau; Rebecca A Dagg; Sarah-Jane Schramm; Antonia Pritchard; Ken Dutton-Regester; Felicity Newell; Anna Fitzgerald; Catherine A Shang; Sean M Grimmond; Hilda A Pickett; Jean Y Yang; Jonathan R Stretch; Andreas Behren; Richard F Kefford; Peter Hersey; Georgina V Long; Jonathan Cebon; Mark Shackleton; Andrew J Spillane; Robyn P M Saw; Núria López-Bigas; John V Pearson; John F Thompson; Richard A Scolyer; Graham J Mann
Journal:  Nature       Date:  2017-05-03       Impact factor: 49.962

3.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

4.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

Authors:  Georgina V Long; Axel Hauschild; Mario Santinami; Victoria Atkinson; Mario Mandalà; Vanna Chiarion-Sileni; James Larkin; Marta Nyakas; Caroline Dutriaux; Andrew Haydon; Caroline Robert; Laurent Mortier; Jacob Schachter; Dirk Schadendorf; Thierry Lesimple; Ruth Plummer; Ran Ji; Pingkuan Zhang; Bijoyesh Mookerjee; Jeff Legos; Richard Kefford; Reinhard Dummer; John M Kirkwood
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245

5.  Clinically amelanotic or hypomelanotic melanoma: Anatomic distribution, risk factors, and survival.

Authors:  Edmund Wee; Rory Wolfe; Catriona Mclean; John W Kelly; Yan Pan
Journal:  J Am Acad Dermatol       Date:  2018-10       Impact factor: 11.527

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.